An interventional study of PDX drug sensitivity testing in Sarcoma, sponsored by Champions Oncology. Terminated at 1 site in Canada. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2017-10-06.
Sponsored by Champions Oncology · Not applicable, Interventional, and Diagnostic
Patients with recurrent or metastatic sarcoma will be consented to develop a patient derived xenograft (PDX or TumorGraft) model of their tumor to perform drug sensitivity testing. The purpose of the study is to evaluate the accuracy of the patient derived xenograft (PDX) model in predicting patient clinical response to the same drug treatment.
1,667 studies on the registry are indexed under Sarcoma; 393 are open to participants now.
This study's enrollment of 17 is below the median of 40 across 1,283 interventional studies indexed under Sarcoma.
Browse Sarcoma studies →This is the only study on the registry with Champions Oncology as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
Other: PDX drug sensitivity testing
Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
Number of patients' whose personalized PDX model accurately predicts clinical response to therapy with same drug treatment.
Overall accuracy as assessed by evaluating Response Evaluation Criteria In Solid Tumors (RECIST) criteria in patient tumor and correlating to tumor regression in PDX model for same drug treatment.
Time frame: 3 years
Number of patients' whose personalized PDX model accurately predicts clinical response to therapy over subsequent lines of therapy.
Overall accuracy as assessed by evaluating RECIST criteria in patient and correlating to tumor regression in PDX model for same drug treatment, over subsequent lines of therapy.
Time frame: 3 years
Factors that impact on engraftment success.
% engraftment of tumor as a function of patient and tumor characteristics.
Time frame: 2 years
Factors that impact time to drug sensitivity testing.
Time to PDX drug sensitivity testing as a function of patient and tumor characteristics.
Time frame: 2 years
This study is terminated, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.